Mizuho Markets Americas LLC Has $25.09 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Mizuho Markets Americas LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.9% in the third quarter, Holdings Channel.com reports. The firm owned 342,147 shares of the biopharmaceutical company’s stock after selling 55,186 shares during the period. Mizuho Markets Americas LLC’s holdings in Halozyme Therapeutics were worth $25,093,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in HALO. Campbell Newman Asset Management Inc. grew its holdings in Halozyme Therapeutics by 0.4% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after acquiring an additional 153 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares in the last quarter. Richardson Financial Services Inc. boosted its stake in Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Brown Advisory Inc. raised its position in Halozyme Therapeutics by 0.6% in the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 224 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its position in shares of Halozyme Therapeutics by 21.6% in the third quarter. Global Retirement Partners LLC now owns 1,413 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 251 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $71.21 on Monday. The stock has a market capitalization of $8.37 billion, a price-to-earnings ratio of 14.99, a PEG ratio of 0.31 and a beta of 0.94. Halozyme Therapeutics, Inc. has a 52-week low of $47.50 and a 52-week high of $79.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock’s 50 day moving average price is $68.70 and its two-hundred day moving average price is $67.46.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same period in the prior year, the firm earned $1.27 earnings per share. Halozyme Therapeutics’s revenue was up 22.1% on a year-over-year basis. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Ratings Changes

HALO has been the topic of a number of analyst reports. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Friday, December 19th. TD Cowen raised their target price on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $78.80.

Insiders Place Their Bets

In related news, COO Cortney Caudill sold 4,263 shares of the stock in a transaction on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total value of $277,904.97. Following the transaction, the chief operating officer directly owned 12,737 shares in the company, valued at $830,325.03. This trade represents a 25.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 45,661 shares of company stock worth $3,139,257. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.